Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2009 - 2026)

Dr Reddys Laboratories has reported Non-Current Deferred Tax Liability for 18 years, with the latest figure at $171.2 million in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 1.39% year-over-year to $171.2 million in Q2 2026; TTM through Jun 2026 was $171.2 million, a 1.39% increase from a year earlier, with the FY2026 full-year figure at $166.0 million, up 0.61% from the prior year.
• Non-Current Deferred Tax Liability was $171.2 million for Q2 2026 at Dr Reddys Laboratories, up from $170.3 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $171.2 million in Q2 2026, with the low at $576967.2 in Q3 2022.
• Average Non-Current Deferred Tax Liability over 5 years is $80.1 million, with a median of $34.6 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Non-Current Deferred Tax Liability plunged 82.79% in 2022, then surged 13282.2% in 2024.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.9 million in 2022, then surged by 509.5% to $11.9 million in 2023, then surged by 1285.81% to $164.6 million in 2024, then advanced by 0.8% to $165.9 million in 2025, then grew by 3.18% to $171.2 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $171.2 million (Q2 2026), $170.3 million (Q1 2026), and $165.9 million (Q4 2025), per Business Quant data.